TG Therapeutics, Inc. (NASDAQ:TGTX) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

A number of other research analysts have also recently issued reports on TGTX. Raymond James Financial, Inc. reiterated a “buy” rating on shares of TG Therapeutics in a research report on Friday, April 21st. Jefferies Group LLC initiated coverage on TG Therapeutics in a report on Tuesday, April 25th. They set a “buy” rating and a $23.00 price target on the stock. FBR & Co restated a “buy” rating on shares of TG Therapeutics in a report on Monday, May 1st. Zacks Investment Research cut TG Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 16th. Finally, ValuEngine upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.67.

TG Therapeutics (NASDAQ TGTX) opened at 10.40 on Friday. The firm’s market capitalization is $641.22 million. TG Therapeutics has a 52-week low of $4.10 and a 52-week high of $15.35. The firm’s 50-day moving average is $11.10 and its 200-day moving average is $9.77.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Friday, May 5th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.42) by $0.10. TG Therapeutics had a negative net margin of 60,613.16% and a negative return on equity of 135.31%. The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. On average, equities analysts expect that TG Therapeutics will post ($1.81) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Rating Lowered by BidaskClub” was first published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/07/tg-therapeutics-inc-nasdaqtgtx-stock-rating-lowered-by-bidaskclub.html.

In related news, CFO Sean A. Power sold 59,976 shares of TG Therapeutics stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $11.09, for a total value of $665,133.84. Following the transaction, the chief financial officer now directly owns 477,464 shares of the company’s stock, valued at $5,295,075.76. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 16.70% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of the company. Legal & General Group Plc raised its position in TG Therapeutics by 4.1% in the first quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 384 shares in the last quarter. BB&T Securities LLC bought a new position in TG Therapeutics during the first quarter worth approximately $121,000. Hollencrest Securities LLC bought a new position in TG Therapeutics during the second quarter worth approximately $121,000. Thompson Davis & CO. Inc. bought a new position in TG Therapeutics during the first quarter worth approximately $154,000. Finally, Bank of America Corp DE raised its position in TG Therapeutics by 11.0% in the first quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock worth $164,000 after buying an additional 1,395 shares in the last quarter. 45.68% of the stock is currently owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.